HY2026

12 February 2026; Company Announcement - Pro Medicus Limited Interim Results - Acrobat pdf 150k Highlights Revenue from ordinary activities $124.8m – up 28.4% Underlying profit before tax $90.7m – up 29.7% Reported net profit after tax $171.2m – up 230.9% Underlying EBIT margins increase to 73% (HY25: 72%) Cash and other financial assets $221.8m – up 5.3% Company remains debt-free Fully franked interim dividend 32c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a half-year underlying net profit of $67.3 million for the six months to the end of December 2025, 29.7% higher than for the previous corresponding period. Revenue from ordinary activities was $124.8 million, up 28.4%. Reported net profit after tax was $171.2 million, up 230.9%. This includes unrealised gains of $149.1 million before tax, from the company’s $10 million hybrid debt and equity investment in 4D Medical Limited in July 2025. Pro Medicus’ cash and other financial assets at December 2025 were $221.8 million, an increase of 5.3% despite paying out increased dividends, two share buybacks and the $10M investment in 4D Medical. The company announced a fully franked interim dividend of 32c per share. The company remains debt-free. During the period the company announced seven new contracts: A 10-year $A170 million contract with University of Colorado on 3 July 2025 (full stack and cardiology, go live May 2026) A 5-year $10 million contract with University Hospital Heidelberg on 8 October 2025 (Viewer and Archive, go live March 2026) A 5-year $A44 million contract with Advanced Radiology Management on 17 November 2025 (Viewer, go live second half 2026) A 5-year $A6.5 million contract with Children’s of Alabama on 24 November 2025 (full stack, implemented August